• Something wrong with this record ?

Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure

J. Vodicka, M. Pesta, V. Kulda, K. Houfkova, B. Vankova, J. Sebek, M. Skala, J. Fichtl, K. Prochazkova, O. Topolcan

. 2020 ; 9 (12) : . [pub] 20201204

Language English Country Switzerland

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026339

The aim of the study was to compare the prognostic significance of lymph node status of patients with lung cancer analyzed by three different methods: hematoxylin and eosin (H&E), immunohistochemistry of cytokeratin 19 (IHC CK19), and One-Step Nucleic Acid Amplification (OSNA). The clinical relevance of the results was evaluated based on relation to prognosis; the disease-free interval (DFI) and overall survival (OS) were analyzed. During radical surgical treatment, a total of 1426 lymph nodes were obtained from 100 patients, creating 472 groups of nodes (4-5 groups per patient) and examined by H&E, IHC CK19 and OSNA. The median follow-up was 44 months. Concordant results on the lymph node status of the H&E, IHC CK19 and OSNA examinations were reported in 78% of patients. We recorded shorter OS in patients with positive results provided by both OSNA and H&E. The study demonstrated a higher percentage of detected micrometastases in lymph nodes by the OSNA method. However, the higher sensitivity of the OSNA, with the cut-off value 250 copies of mRNA of CK19/μL, resulted in a lower association of OSNA positivity with progress of the disease compared to H&E. Increasing the cut-off to 615 copies resulted in an increase in concordance between the OSNA and H&E, which means that the higher cut-off is more relevant in the case of lung tumors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026339
003      
CZ-PrNML
005      
20220906143222.0
007      
ta
008      
211013s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cells9122611 $2 doi
035    __
$a (PubMed)33291819
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vodicka, Josef $u Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic
245    10
$a Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure / $c J. Vodicka, M. Pesta, V. Kulda, K. Houfkova, B. Vankova, J. Sebek, M. Skala, J. Fichtl, K. Prochazkova, O. Topolcan
520    9_
$a The aim of the study was to compare the prognostic significance of lymph node status of patients with lung cancer analyzed by three different methods: hematoxylin and eosin (H&E), immunohistochemistry of cytokeratin 19 (IHC CK19), and One-Step Nucleic Acid Amplification (OSNA). The clinical relevance of the results was evaluated based on relation to prognosis; the disease-free interval (DFI) and overall survival (OS) were analyzed. During radical surgical treatment, a total of 1426 lymph nodes were obtained from 100 patients, creating 472 groups of nodes (4-5 groups per patient) and examined by H&E, IHC CK19 and OSNA. The median follow-up was 44 months. Concordant results on the lymph node status of the H&E, IHC CK19 and OSNA examinations were reported in 78% of patients. We recorded shorter OS in patients with positive results provided by both OSNA and H&E. The study demonstrated a higher percentage of detected micrometastases in lymph nodes by the OSNA method. However, the higher sensitivity of the OSNA, with the cut-off value 250 copies of mRNA of CK19/μL, resulted in a lower association of OSNA positivity with progress of the disease compared to H&E. Increasing the cut-off to 615 copies resulted in an increase in concordance between the OSNA and H&E, which means that the higher cut-off is more relevant in the case of lung tumors.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a keratin-19 $x genetika $7 D053539
650    _2
$a nádory plic $x diagnóza $x patologie $x chirurgie $7 D008175
650    _2
$a lymfatické uzliny $x patologie $7 D008198
650    12
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a staging nádorů $7 D009367
650    _2
$a techniky amplifikace nukleových kyselin $x metody $7 D021141
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 323 00 Plzen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 323 00 Plzen, Czech Republic
700    1_
$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Karlovarska 48, 301 66 Plzen, Czech Republic
700    1_
$a Houfkova, Katerina $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, 323 00 Plzen, Czech Republic
700    1_
$a Vankova, Bohuslava $u Department of Pathology, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, Edvarda Benese 13, 305 99 Plzen, Czech Republic
700    1_
$a Sebek, Jakub $u Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic
700    1_
$a Skala, Martin $u Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic
700    1_
$a Fichtl, Jakub $u Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic
700    1_
$a Procházková, Kristýna, $u Department of Surgery, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, alej Svobody 80, 304 60 Plzen, Czech Republic $d 1982- $7 xx0227765
700    1_
$a Topolcan, Ondrej $u Department of Immunochemistry Diagnostics, Faculty Hospital Plzen, Faculty of Medicine in Pilsen, Charles University, Edvarda Benese 13, 305 99 Plzen, Czech Republic
773    0_
$w MED00194911 $t Cells $x 2073-4409 $g Roč. 9, č. 12 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33291819 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20220906143218 $b ABA008
999    __
$a ok $b bmc $g 1715147 $s 1146846
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 12 $e 20201204 $i 2073-4409 $m Cells $n Cells $x MED00194911
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options